Abrupt termination of vitamin C from ICU patients may increase mortality: secondary analysis of the LOVIT trial.
Harri HemiläElizabeth ChalkerPublished in: European journal of clinical nutrition (2022)
The increased mortality in the vitamin C group in the LOVIT trial is not explained by ongoing vitamin C administration, but by the abrupt termination of vitamin C. The LOVIT trial findings should not be interpreted as evidence against vitamin C therapy for critically ill patients.
Keyphrases
- phase iii
- study protocol
- phase ii
- clinical trial
- end stage renal disease
- cardiovascular events
- ejection fraction
- chronic kidney disease
- newly diagnosed
- intensive care unit
- risk factors
- randomized controlled trial
- open label
- cardiovascular disease
- type diabetes
- coronary artery disease
- patient reported outcomes
- mechanical ventilation
- patient reported